Bio/Pharma Business

Competition seeks to encourage academic research and accelerate drug delivery applications.

In 2013, the EMA's Committee for Medicinal Products for Human Use recommended 81 medicines for human use for marketing authorization, compared with 57 in 2012.

Generics, market dynamics, and global demand are changing drug spending patterns.

Janssen's donation program will improve access to the company's approved HIV medicines for children and adolescents in sub-Saharan Africa.

Former US President Jimmy Carter and Pfizer commemorate the 15th anniversary of the International Trachoma Initiative to end blinding trachoma by the year 2020.

The Bristol-Myers Squibb Foundation is awarding 10 grants to fund programs for veterans and their families.

Almost 400 new medicines for infectious diseases, including viral infections, bacterial infections, fungal infections and parasitic infections.

GDUFA is off to a good start from a facility inspection perspective, but there are storm clouds on the horizon.

Jill E. Sackman, D.V.M., PhD, senior consultant at Numerof & Associates, Inc. discusses the market forces impacting biopharmaceutical manufacturing

Pharmaceutical Technology takes a look at the major deals and moves of 2013.

A roundup of developments in global health and sustainability from the bio/pharmaceutical industry, its suppliers, and other public and private organizations.

Global spending on medicines is expected to meet the $1 trillion threshold in 2014 and reach $1.17 trillion by 2017, according to a recent report by the IMS Institute for Healthcare Informatics

Legislators agree on a limited bill affirming FDA authority over compounders while setting up a process for national drug tracking.

For its use of innovative technology for the production of seasonal and pandemic influenza vaccines, the Novartis Holly Springs, North Carolina facility was the Overall Winner of the 2013 Facility of the Year Award issued by the International Society for Pharmaceutical Engineering (ISPE).

Israel's diverse population, high-quality healthcare system, and resilience to global financial stress make it a strong partner for R&D, clinical research, and market growth.

Siegfried Schmitt, principal consultant at PAREXEL, discusses the state of drug manufacturing in India.

The rising cost of drug development and the decreasing proportion of drug-naive population in the US and European markets are driving international pharmaceutical companies to consider emerging markets as a location to conduct their clinical trials. Asia stands out among the emerging markets given its double-digit growth rates.

Ongoing changes create new opportunities for CROs and CMOs.

Pharmaceutical Technology's 2013 Employment Survey reveals some optimism for the industry's future performance, but ongoing concerns about individual job prospects.

Industry mergers, acquisitions and downsizing contribute to uncertainty in job security in the European bio/pharmaceutical market.

American Association of Pharmaceutical Scientists Foundation to assist current and future scientists.

Drug Quality and Security Act gives FDA authority over compounding pharmacies.

Thermo Fisher must divest of cell culture media and sera lines, and other businesses, in purchase of Life Technologies.

New CDMO to be formed from the combination of DSM Pharmaceutical Products and Patheon in a $2.6-billion transaction.

Grifols expands and diversifies portfolio with acquisition of diagnostic business.

Biotechnology Industry Organization President James Greenwood writes senators in support of Start-up Jobs and Innovation Act.

A roundup of developments in global health and sustainability from the bio/pharmaceutical industry, its suppliers, and other public and private organizations.

Through its educational and networking opportunities, the American Association of Pharmaceutical Scientists plays an important role in partnering throughout the drug- development and commercialization process.

New partnership aims to eliminate months from the typical transition time required to move chemistry from the laboratory into commercial applications.

A roundup of developments in global health and sustainability from the bio/pharmaceutical industry, its suppliers, and other public and private organizations.